Fecha: martes 16 de abril

Lugar: Aula Magna, Clínica Alemana de Santiago. Av. Vitacura 5951.

Hora: 8:30 a 9:30 horas.

Temas que se discutirán:

• Por qué y cómo aparecen los medicamentos biológicos en el arsenal terapéutico
• Impacto de los medicamentos biológicos en el gasto de Salud
• ¿Qué es un biosimilar?
• Regulación vigente para los biosimilares
• Proceso de desarrollo de la regulación vigente de los biosimilares en Europa (EMA)
• ¿Los biosimilares aumentarán el acceso a los medicamentos biológicos?
• Futuro de los biosimilares

Expositor

Dr. Udo Mueller

Dr. Mueller holds a MD degree in Medical Oncology and a PhD degree in Clinical Pharmacology. As part of his medicaI and pharmacology training he worked at the PharmacologicaI lnstitute Mario Negri in Milan (ltaly), at the Grace Cancer Drug Center at the Roswell Park Cancer Institute in Buffalo NY (USA), at Institute Bordet in Brussels (Belgium) and the Royal Prince Alfred Hospital in Sydney (Australia). Dr. Mueller was the head of a Clinical Pharmacology Laboratory Unit for anticancer drugs and he had teaching obligations at the Medical Faculty of Berlin University. Before joining the pharmaceutical industry, his work focused on cancer patient medical care and clinical cancer research.

In his recent position as a Global Medical Director for Teva Pharmaceuticals, Dr. Mueller is responsible for the medical support of Teva´s oncology and biosimilar pipeline  and marketed products.